Cargando…
Evans Syndrome in Children: Long-Term Outcome in a Prospective French National Observational Cohort
Evans syndrome (ES) is a rare autoimmune disorder whose long-term outcome is not well known. In France, a collaborative pediatric network set up via the National Rare Disease Plan now provides comprehensive clinical data in children with this disease. Patients aged less than 18 years at the initial...
Autores principales: | Aladjidi, Nathalie, Fernandes, Helder, Leblanc, Thierry, Vareliette, Amélie, Rieux-Laucat, Frédéric, Bertrand, Yves, Chambost, Hervé, Pasquet, Marlène, Mazingue, Françoise, Guitton, Corinne, Pellier, Isabelle, Roqueplan-Bellmann, Françoise, Armari-Alla, Corinne, Thomas, Caroline, Marie-Cardine, Aude, Lejars, Odile, Fouyssac, Fanny, Bayart, Sophie, Lutz, Patrick, Piguet, Christophe, Jeziorski, Eric, Rohrlich, Pierre, Lemoine, Philippe, Bodet, Damien, Paillard, Catherine, Couillault, Gérard, Millot, Frédéric, Fischer, Alain, Pérel, Yves, Leverger, Guy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586429/ https://www.ncbi.nlm.nih.gov/pubmed/26484337 http://dx.doi.org/10.3389/fped.2015.00079 |
Ejemplares similares
-
Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden
por: Pincez, Thomas, et al.
Publicado: (2021) -
Real-world experience with CLAIRYG® 50 mg/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immmune thrombocytopenia: a post-approval safety study
por: Mahlaoui, Nizar, et al.
Publicado: (2023) -
RASopathies: From germline mutations to somatic and multigenic diseases
por: Riller, Quentin, et al.
Publicado: (2021) -
PD-L1 is expressed on human activated naive effector CD4(+) T cells. Regulation by dendritic cells and regulatory CD4(+) T cells
por: Mazerolles, Fabienne, et al.
Publicado: (2021) -
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951
por: Mondelaers, Veerle, et al.
Publicado: (2017)